BMS’ confirmatory trial of Krazati hits primary endpoint following 2022 accelerated approval

Bris­tol My­ers Squibb scored a con­fir­ma­to­ry tri­al win for Kraza­ti, the KRAS in­hibitor it picked up ear­li­er this year through its $4.8 bil­lion ac­qui­si­tion of Mi­rati.

In De­cem­ber 2022, Kraza­ti won an ac­cel­er­at­ed ap­proval for non-small cell lung can­cer pa­tients, be­com­ing the sec­ond ap­proved KRAS in­hibitor in the US be­hind Am­gen’s Lumakras. Both drugs tar­get a mu­ta­tion called G12C in the hopes of halt­ing un­con­trolled ma­lig­nant cell growth.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.